Fighting for a cancer free future
Cancer is the second leading cause of death globally and is responsible for over 9 million deaths every year. Globally, about 1 in 6 deaths is due to cancer.
Our research and key clinical collaborators put us at the cutting edge of cancer glycomics, which focuses on the interactions of sugar molecules and the proteins that recognise sugar molecules on the surface of cancer cells.
The Institute for Glycomics and the Australian Centre for Cancer Glycomics (A2CG) are taking a highly integrated, systematic approach to identifying important cancer biomarkers and tumour-associated carbohydrate antigens (TACAs), underpinned by a strategic focus geared towards translational outcomes. Our team of research scientists are dedicated to understanding how cancer glycans can sketch the blueprint for the next wave of diagnostics, drugs and vaccines. Through our vision of harnessing this unique research platform to identify new solutions to cancer, we aim to improve the future of those living with this intractable disease.
Our research and key clinical collaborators put us at the cutting edge of 'cancer glycomics', which focuses on the interactions of sugar molecules and the proteins that recognise sugar molecules on the surface of cancer cells.
Mark von Itzstein AO
Stomach cancer, also known as gastric cancer, usually begins in the lining in the upper part of the stomach.
Stomach cancer is a relatively common cancer in Australia, however it is rare in people under 50 years of age and affects more men than women.
In 2016, 2,197 new cases of stomach cancer were diagnosed in Australia. In 2018, there were 1,138 deaths due to stomach cancer in Australia. (Source: Cancer Council).
Globally, according to the World Health Organization, it is one of the most common cancers, with 1.03 million cases confirmed in 2018, resulting in 783,000 deaths that same year.